VYNE Therapeutics Shares Scheduled to Reverse Split on Monday, July 27th (NASDAQ:VYNE)

Shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) are set to reverse split on Monday, July 27th. The 1-50 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, July 26th.

VYNE Therapeutics Trading Up 0.5%

Shares of VYNE opened at $0.90 on Thursday. The firm has a market capitalization of $29.96 million, a P/E ratio of -2.36 and a beta of 2.00. The stock’s fifty day simple moving average is $0.68 and its 200 day simple moving average is $0.63. VYNE Therapeutics has a twelve month low of $0.28 and a twelve month high of $1.59.

VYNE Therapeutics (NASDAQ:VYNE) last issued its earnings results on Friday, May 15th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.10. VYNE Therapeutics had a negative return on equity of 70.42% and a negative net margin of 4,726.21%.The business had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.20 million. Sell-side analysts predict that VYNE Therapeutics will post -1.1 earnings per share for the current year.

VYNE Therapeutics Announces Dividend

The company also recently disclosed a special dividend, which will be paid on Thursday, July 23rd. Stockholders of record on Wednesday, July 22nd will be issued a $0.38 dividend.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of VYNE Therapeutics in a report on Monday, May 4th. Three equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Reduce”.

Institutional Trading of VYNE Therapeutics

Several large investors have recently bought and sold shares of VYNE. XTX Topco Ltd purchased a new stake in shares of VYNE Therapeutics during the fourth quarter valued at approximately $46,000. Rangeley Capital LLC lifted its position in shares of VYNE Therapeutics by 18.1% during the first quarter. Rangeley Capital LLC now owns 118,064 shares of the company’s stock worth $71,000 after purchasing an additional 18,064 shares in the last quarter. Two Sigma Investments LP purchased a new position in shares of VYNE Therapeutics in the third quarter valued at $74,000. Geode Capital Management LLC boosted its stake in shares of VYNE Therapeutics by 64.2% in the fourth quarter. Geode Capital Management LLC now owns 225,152 shares of the company’s stock valued at $131,000 after purchasing an additional 88,030 shares during the period. Finally, ADAR1 Capital Management LLC purchased a new position in shares of VYNE Therapeutics in the fourth quarter valued at $147,000. Institutional investors and hedge funds own 83.78% of the company’s stock.

VYNE Therapeutics Company Profile

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.